From 2006 to 2019, age-adjusted mortality for liver disease in the US increased by 14% overall and by 24% during COVID, from 2019 through 2021.

Phase 3 results show the investigational drug norucholic acid is superior to placebo in halting disease progression.

The parasite, which claims nearly 70,000 lives each year, usually causes nothing more than diarrhoea, but sometimes it ...

The Liver Transplant Comorbidity Index, developed from FrAILT study results, identified patients at high risk for mortality at 3 years post-liver transplant.